Prostate cancer: Evolution or revolution?

Journal of Clinical Oncology

Volumn 29, Issue 27, 2011, Pages 3595-3598

  Small, Eric J ^a   De Bono, Johann Sebastian ^b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b INSTITUTE OF CANCER RESEARCH   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

4 [3 [4 CYANO 3 (TRIFLUOROMETHYL)PHENYL] 5,5 DIMETHYL 4 OXO 2 THIOXO 1 IMIDAZOLIDINYL] 2 FLUORO N METHYLBENZAMIDE; ABIRATERONE; ABIRATERONE ACETATE; BRCA2 PROTEIN; CABAZITAXEL; DENOSUMAB; DOCETAXEL; ESTRAMUSTINE PHOSPHATE; IPILIMUMAB; KETOCONAZOLE; MITOXANTRONE; ORTERONEL; PLACEBO; PREDNISONE; PROVENGE; SAMARIUM; SAMARIUM 153; STRONTIUM; STRONTIUM 89; TAXANE DERIVATIVE; ZOLEDRONIC ACID;

ADVANCED CANCER; ANDROGEN DEPRIVATION THERAPY; CANCER THERAPY; CASTRATION RESISTANT PROSTATE CANCER; CLINICAL PRACTICE; CLINICAL TRIAL (TOPIC); CONFERENCE PAPER; DRUG DOSE SEQUENCE; GENE MUTATION; HORMONE RESISTANCE; HUMAN; MALE; MELANOMA; METASTASIS; NEUROPATHY; PRIORITY JOURNAL; PROSTATE CANCER;

HUMANS; MALE; NEOPLASMS; PROSTATIC NEOPLASMS;

EID: 80053088169     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2011.37.8653     Document Type: Conference Paper

References (27)

1. Small EJ, Klein EA: Challenges and future directions in the prevention and management of prostate cancer. J Clin Oncol 23:8143-8145, 2005 (Pubitemid 46217469)
2. Petrylak DP, Ankerst DP, Jiang CS, et al: Evaluation of prostate-specific antigen declines for surrogacy in patients treated on SWOG 99-16. J Natl Cancer Inst 98:516-521, 2006 (Pubitemid 43898814)
3. Tannock IF, De Wit R, Berry WR, et al: Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med 351:1502-1512, 2004 (Pubitemid 39315317)
4. Porter AT, McEwan AJ, Powe JE, et al: Results of a randomized phase-III trial to evaluate the efficacy of strontium-89 adjuvant local field external beam irradiation in the management of endocrine resistant metastatic prostate cancer. Int J Radiat Oncol Biol Phys 25:805-813, 1993 (Pubitemid 23123384)
5. Serafini AN, Houston SJ, Resche I, et al: Palliation of pain associated with metastatic bone cancer using samarium-153 lexidronam: A double-blind placebo-controlled clinical trial. J Clin Oncol 16:1574-1581, 1998 (Pubitemid 28175783)
6. Saad F, Gleason DM, Murray R, et al: A randomized, placebo-controlled trial of zoledronic acid in patients with hormone-refractory metastatic prostate carcinoma. J Natl Cancer Inst 94:1458-1468, 2002
7. Tannock IF, Osoba D, Stockler MR, et al: Chemotherapy with mitoxantrone plus prednisone or prednisone alone for symptomatic hormone-resistant prostate cancer: A Canadian randomized trial with palliative end points. J Clin Oncol 14:1756-1764, 1996 (Pubitemid 26185452)
8. Small EJ, Halabi S, Dawson NA, et al: Antiandrogen withdrawal alone or in combination with ketoconazole in androgen-independent prostate cancer patients: A phase III trial (CALGB 9583). J Clin Oncol 22:1025-1033, 2004 (Pubitemid 41095034)
9. Chen CD, Welsbie DS, Tran C, et al: Molecular determinants of resistance to antiandrogen therapy. Nat Med 10:33-39, 2004 (Pubitemid 38524696)
10. Ryan CJ, Tindall DJ: Androgen receptor rediscovered: The new biology and targeting the androgen receptor therapeutically. J Clin Oncol 29:3651-3658, 2011
11. De Bono JS, Logothetis CJ, Molina A, et al: Abiraterone and increased survival in metastatic prostate cancer. N Engl J Med 364:1995-2005, 2011
12. Rubin MA, Maher CA, Chinnaiyan AM: Common gene rearrangements in prostate cancer. J Clin Oncol 29:3659-3668, 2011
13. Tomlins SA, Rhodes DR, Perner S, et al: Recurrent fusion of TMPRSS2 and ETS transcription factor genes in prostate cancer. Science 310:644-648, 2005 (Pubitemid 41528150)
14. Tomlins SA, Laxman B, Dhanasekaran SM, et al: Distinct classes of chromosomal rearrangements create oncogenic ETS gene fusions in prostate cancer. Nature 448:595-599, 2007 (Pubitemid 47206938)
15. Bastus NC, Boyd LK, Mao X, et al: Androgen-induced TMPRSS2:ERG fusion in nonmalignant prostate epithelial cells. Cancer Res 70:9544-9548, 2010
16. Lin C, Yang L, Tanasa B, et al: Nuclear receptor-induced chromosomal proximity and DNA breaks underlie specific translocations in cancer. Cell 139:1069-1083, 2009
17. Fong PC, Boss DS, Yap TA, et al: Inhibition of poly(ADP-ribose) polymerase in tumors from BRCA mutation carriers. N Engl J Med 361:123-134, 2009
18. Montie JE, Smith JA: Whitmoreisms: Memorable quotes from Willet F. Whitmore, Jr, MD. Urology 63:207-209, 2004 (Pubitemid 38147594)
19. Cooperberg MR, Carroll PR, Klotz L: Active surveillance for prostate cancer: Progress and promise. J Clin Oncol 29:3669-3676, 2011
20. Kantoff PW, Higano CS, Shore ND, et al: Sipuleucel-T immunotherapy for castration-resistant prostate cancer. N Engl J Med 363:411-422, 2010
21. Fizazi K, Carducci M, Smith M, et al: Denosumab versus zoledronic acid for treatment of bone metastases in men with castration-resistant prostate cancer: A randomised, double-blind study. Lancet 377:813-822, 2011
22. De Bono JS, Oudard S, Ozguroglu M, et al: Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: A randomised open-label trial. Lancet 376:1147-1154, 2010
23. Cha E, Fong L: Immunotherapy for prostate cancer: Biology and therapeutic approaches. J Clin Oncol 29:3677-3685, 2011
24. Seruga B, Tannock IF: Chemotherapy-based treatment for castration-resistant prostate cancer. J Clin Oncol 29:3686-3694, 2011
25. Scher HI, Morris MJ, Basch E, et al: End points and outcomes in castration-resistant prostate cancer: From clinical trials to clinical practice. J Clin Oncol 29:3695-3704, 2011
26. Petrylak DP, Dawson NA, Gardner T, et al: Persistence of immunotherapy survival effects of sipuleucel-T and relationship to postrandomization docetaxel use in phase III studies. J Clin Oncol 28:354s, 2010 (suppl; abstr 4551)
27. Saylor PJ, Lee RJ, Smith MR: Emerging therapies to prevent skeletal morbidity in men with prostate cancer. J Clin Oncol 29:3705-3714, 2011